Chen SK, et al. - Researchers analyzed 11,248 individuals to examine the risk of hospitalized infection among subjects with rheumatoid arthritis (RA) who initiated abatacept vs a TNF inhibitor (TNFi). They noted the incidence rates (IR) per 1000 person-years for any hospitalized infection, 37 among abatacept initiators and 47 in TNFi initiators. They recorded a lower risk of secondary outcomes for abatacept for pulmonary infections and comparable to TNFi for the remaining consequences in this large cohort of RA cases who used abatacept or TNFi as a first or second-line biologic agent.